On the fly News and insights, exclusive to thefly.com

ARNA

Arena Pharmaceuticals

$65.46 /

+6.76 (+11.52%)

, BMY

Bristol-Myers

$60.31 /

+ (+0.00%)

10:57
06/02/20
06/02
10:57
06/02/20
10:57

Arena Pharmaceuticals price target raised to $88 from $68 at Cantor Fitzgerald

Cantor Fitzgerald analyst Alethia Young raised the firm's price target on Arena Pharmaceuticals (ARNA) to $88 from $68 and reiterates an Overweight rating on the shares. Bristol Meyers' (BMY) positive topline data this morning from the pivotal study of its sphingosine-1-phosphate ozanimod in ulcerative colitis is a "positive readthrough" to Arena's etrasimod ulcerative colitis program, Young tells investors in a research note. The analyst increased her probability of success 80% from 75% and is now "very confident" in the Phase 3 success of etrasimod. Young also thinks that S1P1 as a class is shaping up to be a "big commercial opportunity" and increased her peak sales to $3B. Arena shares to be up at least 10% today on Bristol's news given that ozanimod and etrasimod are both S1P1s and this is the first positive Phase 3 readout for the class in ulcerative colitis, says the analyst. Arena Pharmaceuticals in morning trading is up 13%, or $7.49, to $6.19.

ARNA

Arena Pharmaceuticals

$65.46 /

+6.76 (+11.52%)

BMY

Bristol-Myers

$60.31 /

+ (+0.00%)

  • 12

    Jun

  • 06

    Aug

  • 17

    Aug

  • 03

    Sep

ARNA Arena Pharmaceuticals
$65.46 /

+6.76 (+11.52%)

05/18/20
Fly Intel: Top five analyst initiations
05/18/20 Jefferies
Arena Pharmaceuticals initiated with a Buy at Jefferies
05/18/20 Jefferies
Arena Pharmaceuticals initiated with a Buy at Jefferies
03/31/20 Guggenheim
Guggenheim starts Arena at Buy on 'pipeline-in-a-product' etrasimod
BMY Bristol-Myers
$60.31 /

+ (+0.00%)

06/02/20 Oppenheimer
Ayala Pharmaceuticals initiated with an Outperform at Oppenheimer
05/13/20 Stifel
Bluebird's ide-cel remains approvable despite FDA's 'strict stance,' says Stifel
05/13/20 Piper Sandler
Bluebird should be able to easily address RTF issues, says Piper Sandler
05/12/20 Oppenheimer
Bluebird Bio price target lowered to $111 from $122 at Oppenheimer

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.